A Phase 3 interventional study of Hydrocortisone and Sodium Chloride 9mg/mL in Covid-19 and Hypoxia, sponsored by Scandinavian Critical Care Trials Group. Completed at 14 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-21.
Sponsored by Scandinavian Critical Care Trials Group · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 99 studies in COVID-19 with a site in Denmark — 10 open to participants now, 12 under way, 3 of them phase 3. COVID-19 · Denmark.
Among the 99 studies in COVID-19 with a site in Denmark, this one is the 48th largest by enrollment of the 55 interventional ones that give a count, is one of 55 that started in 2020, is one of 25 in phase 3, and was the 10th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →10 of the 99 studies in COVID-19 with a site in Denmark are open now. Recruiting first, the newest first:
Pfizer · Sites in Denmark, United States, Argentina and 15 more countries
Ages 18+
Pfizer · Sites in Denmark, United States, Argentina and 16 more countries
Ages 12+
Hvidovre University Hospital · Sites in Denmark
Ages 18+ · Healthy volunteers
AstraZeneca · Sites in Denmark, United States, Argentina and 36 more countries
Ages 18+
Ditte Gertz Mogensen · Sites in Denmark
Ages 18+
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
99 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 26 · Phase 4 6
First in 2017; this study’s year is marked. 55 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 102 across 4,369 interventional studies indexed under COVID-19.
Median enrollment 317 across the 55 interventional studies, 417 across the 43 observational. Of the 70 that completed or were terminated, 20 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 99 have an industry lead sponsor. The 10 most frequent:
Scandinavian Critical Care Trials Group is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Scandinavian Critical Care Trials Group has 2 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
3 of the studies in COVID-19 with a site in Denmark that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add all 3 to your calendar (.ics) → With an account.
Among the 99 studies in COVID-19 with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
We aim to assess the benefits and harms of low-dose hydrocortisone in patients with COVID-19 and severe hypoxia.
Background: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has caused a pandemic of coronavirus disease (COVID-19) with many patients developing severe hypoxic respiratory failure. Many patients have died, and healthcare systems in several countries have been or will be overwhelmed because of a surge of patients needing hospitalisation and intensive care. There is no proven treatment for COVID-19; the care is supportive, including respiratory and circulatory support. For other patient groups with similar critical illness (acute respiratory disease syndrome and septic shock), corticosteroids are used because they reduce the duration of mechanical ventilation, length of stay in the intensive care unit, and potentially also mortality. Corticosteroids have been used in some patients with COVID-19, but the recommendations in clinical guidelines differ; some suggest their use, others against.
Objectives: We aim to assess the effects of low-dose intravenous hydrocortisone on the number of days alive without life-support in adult patients with COVID-19 and severe hypoxia.
Design: Multicentre, parallel-group, centrally randomised, stratified, blinded, clinical trial.
Population: Adult patients with documented COVID-19 receiving at least 10 L/min of oxygen independent of delivery system OR mechanical ventilation.
Experimental intervention: Continuous IV infusion of hydrocortisone 200 mg daily will be given for 7 days in addition to standard care.
Control intervention: Continuous IV infusion of matching placebo (0.9% saline) will be given in addition to standard care (no corticosteroids).
Outcomes: The primary outcome is days alive without life support (i.e. mechanical ventilation, circulatory support, or renal replacement therapy) at day 28. Secondary outcomes are serious adverse reactions (i.e. anaphylactic reaction to hydrocortisone, new episode of septic shock, invasive fungal infection or clinically important gastrointestinal bleeding); days alive without life support at day 90; days alive and out of hospital at day 90; all-cause mortality at day 28, day 90 and 1 year; and health-related quality of life at 1 year.
Sample size: A total of 1000 participants will be randomised in order to detect a 15% relative reduction in 28-day mortality combined with a 10% reduction in time on life support among the survivors with a power of 85%.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All the following criteria must be fulfilled:
Use of one of the following:
Exclusion Criteria:
We will exclude patients who fulfil any of the following criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Continuous intravenous infusion of hydrocortisone 200 mg over 24 hours (total 104 ml). The trial intervention will be given in addition to standard care. If continuous intravenous infusion is not possible, we will allow the use of bolus injection of the trial medication (50 mg (10 ml) every 6 hours).
Drug: Hydrocortisone
Continuous intravenous infusion of matching isotonic saline (0.9%) placebo at a dose volume of 104 ml over 24 hours in addition to standard care (no corticosteroid treatment). If continuous intravenous infusion is not possible, we will allow the use of bolus injection of matching saline placebo (10 ml every 6 hours).
Drug: Sodium Chloride 9mg/mL
Continuous infusion: 200 mg (104 ml) every 24 hours, Bolus injections: 50 mg (10 ml) every 6 hours, Total treatment duration: 7 days
Also known as: Solu-cortef
Continuous infusion: 104 ml every 24 hours, Bolus injections: 10 ml every 6 hours, Total treatment duration: 7 days
Also known as: Isotonic saline
Days alive without life support at day 28
Days alive without life support (i.e. invasive mechanical ventilation, circulatory support or renal replacement therapy) from randomisation to day 28
Time frame: Day 28 after randomisation
All-cause mortality at day 28
Death from all causes
Time frame: Day 28 after randomisation
Days alive without life support at day 90
Days alive without life support (i.e. invasive mechanical ventilation, circulatory support or renal replacement therapy) from randomisation to day 90
Time frame: Day 90 after randomisation
All-cause mortality at day 90
Death from all causes
Time frame: Day 90 after randomisation
Number of participants with one or more serious adverse reactions
Defined as new episodes of septic shock, invasive fungal infection, clinically important GI bleeding or anaphylactic reaction
Time frame: Day 14 after randomisation
Days alive and out of hospital at day 90
Number of days alive and out of hospital not limited to the index admission
Time frame: Day 90 after randomisation
All-cause mortality at 1 year after randomisation
Death from all causes
Time frame: 1 year after randomisation
Health-related quality of life at 1 year
Assessed by EQ-5D-5L
Time frame: 1 year after randomisation
Health-related quality of life at 1 year
Assessed by EQ-VAS
Time frame: 1 year after randomisation
Plan to share: Yes — Fully de-identified IPD will be shared after the approval by the the trial management committee
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Immediate sharing of protocol, SAP and ICF. CSR will be shared no later than 6 months after last-patient-last-visit
Access criteria: Contact to the trial management committee
Data sharing details ↗ · www.cric.nu
Ran from Apr 2020 to primary completion in Sep 2020, 4 months.
Of 285 non-industry phase 3 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 4 months is below that.
Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 5 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Hydrocortisone
Scandinavian Critical Care Trials Group